USV, a prominent Indian multinational healthcare company, has recently launched Xenia, a new line of medications containing Empagliflozin and its combinations to enhance diabetes care in India. This strategic move aims to provide effective glycemic control and address complications related to heart failure and chronic kidney disease in individuals with Type 2 diabetes. New Hope for Diabetes Patients: USV’s Xenia Empagliflozin Products is a game-changer, making advanced treatment more accessible and affordable.
Comprehensive Product Range
The Xenia product line includes:
Xenia: Empagliflozin tablets available in 10 mg and 25 mg doses.
Xenia M: A combination of Empagliflozin (12.5 mg) with Metformin, offered in 500 mg immediate-release and 1000 mg extended-release formulations.
Xenia ST: Combines Empagliflozin (25 mg) with Sitagliptin (100 mg).
These combinations offer flexible dosing options, reduce the pill burden for patients, and improve access to modern therapy, enabling early treatment to reduce diabetes complications and mortality. More details on these products can be found here.
Addressing a Growing Health Concern
India currently has over 101 million people living with Type 2 diabetes and 136 million with prediabetes. New Hope for Diabetes Patients: USV’s Xenia Empagliflozin Products aims to expand access to modern diabetes care and reinforce USV’s leadership in the segment. USV remains committed to delivering affordable, high-quality therapies for better patient outcomes.
Increased Affordability and Accessibility
With the loss of exclusivity, Empagliflozin and its combinations are now available at one-fifth of their previous cost, enhancing affordability. USV’s extensive reach across metropolitan areas, Tier I, II, and III cities, corporate hospitals, and e-pharmacies ensures Xenia’s accessibility nationwide, including rural areas.
For further insights on diabetes care advancements, you can check this external resource.
USV’s Commitment to Healthcare
The launch of Xenia underscores USV’s dedication to providing affordable, high-quality therapies aimed at improving patient outcomes. By expanding access to modern diabetes care, USV continues to play a pivotal role in addressing India’s diabetes burden and enhancing the quality of life for millions.
#XeniaLaunch #Empagliflozin #DiabetesCare #USVHealthcare #AffordableMedication #Type2Diabetes #HeartHealth #KidneyHealth #ModernDiabetesTreatment #InnoglidePharma
